Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Clearside Biomedical stock

CLSD
US1850631045
A2ALP6

Price

1.06
Today +/-
+0.02
Today %
+2.15 %

Clearside Biomedical stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Clearside Biomedical stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Clearside Biomedical stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Clearside Biomedical stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Clearside Biomedical's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Clearside Biomedical Stock Price History

DateClearside Biomedical Price
12/5/20241.06 undefined
12/5/20241.04 undefined
12/4/20241.02 undefined
12/3/20241.08 undefined
12/2/20241.09 undefined
11/29/20241.06 undefined
11/27/20241.07 undefined
11/26/20241.08 undefined
11/25/20241.08 undefined
11/22/20241.08 undefined
11/21/20241.02 undefined
11/20/20241.05 undefined
11/19/20241.03 undefined
11/18/20241.02 undefined
11/15/20240.99 undefined
11/14/20241.05 undefined
11/13/20241.09 undefined
11/12/20241.11 undefined
11/11/20241.09 undefined
11/8/20241.14 undefined
11/7/20241.11 undefined

Clearside Biomedical Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Clearside Biomedical, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Clearside Biomedical from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Clearside Biomedical’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Clearside Biomedical. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Clearside Biomedical’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Clearside Biomedical’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Clearside Biomedical’s growth potential.

Clearside Biomedical Revenue, EBIT and net profit per share

DateClearside Biomedical RevenueClearside Biomedical EBITClearside Biomedical Net Income
2029e220.02 M undefined101.32 M undefined113.33 M undefined
2028e145.54 M undefined52.07 M undefined68.46 M undefined
2027e78.56 M undefined6.37 M undefined11.6 M undefined
2026e11.41 M undefined-43.1 M undefined-38.06 M undefined
2025e3.55 M undefined-38.08 M undefined-35.84 M undefined
2024e1.43 M undefined-29.57 M undefined-36.87 M undefined
20238.23 M undefined-24.84 M undefined-32.49 M undefined
20221.33 M undefined-30.28 M undefined-32.95 M undefined
202129.58 M undefined-620,000 undefined380,000 undefined
20207.89 M undefined-17.94 M undefined-18.21 M undefined
20192.17 M undefined-30.3 M undefined-30.77 M undefined
201830,000 undefined-82.95 M undefined-82.82 M undefined
2017350,000 undefined-58.41 M undefined-58.98 M undefined
2016520,000 undefined-25.2 M undefined-25.88 M undefined
20150 undefined-17.32 M undefined-17.64 M undefined
20140 undefined-9.82 M undefined-10.19 M undefined
20130 undefined-7.24 M undefined-7.25 M undefined

Clearside Biomedical Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000000272918131178145220
-------250.00314.29-96.55700.00-87.50200.00266.67609.0985.9051.72
------350.00100.0024.14100.0087.50700.00233.3363.648.974.833.18
00000000017000000
-7-10-17-25-58-82-30-180-32-32-36-35-381168113
-42.8670.0047.06132.0041.38-63.41-40.00---12.50-2.788.57-128.95518.1866.18
19.5919.5919.5925.2925.3130.7338.1746.5159.9160.261.81000000
-----------------
Details

Keystats

ⓘ

Revenue and Growth

The Clearside Biomedical Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Clearside Biomedical is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20132014201520162017201820192020202120222023
                     
1.918.2720.2883.6337.6440.8822.617.2930.4448.2628.92
000000001000.17
00000000000
00000000000
0.110.060.20.691.572.072.630.831.71.141.03
2.028.3320.4884.3239.2142.9525.2318.1242.1449.430.12
0.10.210.160.090.890.791.20.940.611.873.87
00000000000
00000000000
00000000000
00000000000
0.021.770.420.40.410.390.360.260.160.030.03
0.121.980.580.491.31.181.561.20.771.93.9
2.1410.3121.0684.8140.5144.1326.7919.3242.9151.334.02
                     
11.8726.8447.310.030.030.030.040.050.060.060.06
0.792.512.7136.89145.62230.48248.77264.58293.41298.98304.95
-11.54-21.72-39.36-65.25-124.22-206.89-237.66-255.87-255.49-288.44-320.92
000-0.01-0.01000000
00000000000
1.127.6310.6571.6621.4223.6211.158.7637.9810.6-15.91
0.251.261.472.595.386.871.2820.941.052.21
0.431.161.992.794.722.923.291.963.74.534.53
0.010.010.010.020.220.135500.210.08
00000000000
001.7303.20.561.330.99000
0.692.435.25.413.5210.4810.99.954.645.796.81
0.2704.247.594.819.423.820000
00000000000
0.050.250.960.160.750.610.90.620.2934.9143.12
0.320.255.27.755.5610.034.720.620.2934.9143.12
1.012.6810.413.1519.0820.5115.6210.574.9340.749.93
2.1310.3121.0584.8140.544.1326.7719.3342.9151.334.02
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Clearside Biomedical provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Clearside Biomedical's financial health and stability.

Assets

Clearside Biomedical's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Clearside Biomedical must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Clearside Biomedical after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Clearside Biomedical's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20132014201520162017201820192020202120222023
-7-10-17-25-58-82-30-180-32-32
00000000000
00000000000
002130-11-15110
0113799791317
00000000000
00000000000
-6-9-13-22-51-79-27-13-10-13-18
0000000000-1
000-4920-332000-1
000-4920-3320000
00000000000
025101-5-4000
712198458013122301
71525865818723310
00000000030-1
00000000000
161214-25-114-51317-19
-6.9-9.26-13.93-22.71-51.39-79.29-27.1-13.18-10.73-13.62-19.91
00000000000

Clearside Biomedical stock margins

The Clearside Biomedical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Clearside Biomedical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Clearside Biomedical.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Clearside Biomedical's sales revenue. A higher gross margin percentage indicates that the Clearside Biomedical retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Clearside Biomedical's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Clearside Biomedical's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Clearside Biomedical's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Clearside Biomedical. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Clearside Biomedical's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Clearside Biomedical Margin History

Clearside Biomedical Gross marginClearside Biomedical Profit marginClearside Biomedical EBIT marginClearside Biomedical Profit margin
2029e95.68 %46.05 %51.51 %
2028e95.68 %35.77 %47.04 %
2027e95.68 %8.11 %14.77 %
2026e95.68 %-377.67 %-333.5 %
2025e95.68 %-1,072.04 %-1,009.06 %
2024e95.68 %-2,062.26 %-2,571.39 %
202395.68 %-302.02 %-394.91 %
202284.21 %-2,276.69 %-2,477.44 %
202195.68 %-2.1 %1.28 %
202095.68 %-227.38 %-230.8 %
201995.68 %-1,396.31 %-1,417.97 %
201895.68 %-276,500 %-276,066.67 %
201795.68 %-16,688.57 %-16,851.43 %
201695.68 %-4,846.15 %-4,976.92 %
201595.68 %0 %0 %
201495.68 %0 %0 %
201395.68 %0 %0 %

Clearside Biomedical Stock Sales Revenue, EBIT, Earnings per Share

The Clearside Biomedical earnings per share therefore indicates how much revenue Clearside Biomedical has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Clearside Biomedical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Clearside Biomedical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Clearside Biomedical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Clearside Biomedical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Clearside Biomedical Revenue, EBIT and net profit per share

DateClearside Biomedical Sales per ShareClearside Biomedical EBIT per shareClearside Biomedical Earnings per Share
2029e2.9 undefined0 undefined1.49 undefined
2028e1.92 undefined0 undefined0.9 undefined
2027e1.04 undefined0 undefined0.15 undefined
2026e0.15 undefined0 undefined-0.5 undefined
2025e0.05 undefined0 undefined-0.47 undefined
2024e0.02 undefined0 undefined-0.49 undefined
20230.13 undefined-0.4 undefined-0.53 undefined
20220.02 undefined-0.5 undefined-0.55 undefined
20210.49 undefined-0.01 undefined0.01 undefined
20200.17 undefined-0.39 undefined-0.39 undefined
20190.06 undefined-0.79 undefined-0.81 undefined
20180 undefined-2.7 undefined-2.7 undefined
20170.01 undefined-2.31 undefined-2.33 undefined
20160.02 undefined-1 undefined-1.02 undefined
20150 undefined-0.88 undefined-0.9 undefined
20140 undefined-0.5 undefined-0.52 undefined
20130 undefined-0.37 undefined-0.37 undefined

Clearside Biomedical business model

Clearside Biomedical Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for the treatment of eye diseases and other medical conditions. The company was founded in 2011 by an experienced team of researchers and developers and is based in Alpharetta, Georgia. Clearside Biomedical Inc's history can be traced back to the groundbreaking research of Professor Henry Edelhauser, a renowned ophthalmologist and leading expert in the field of ophthalmology. Professor Edelhauser had the idea that by injecting drugs directly into the eye, specifically into the back part of the eye, more effective treatment could be achieved. Together with his team, he developed an innovative method for injecting drugs into the vitreous humor of the eye, which Clearside Biomedical Inc uses in its work. The business model of Clearside Biomedical Inc is based on the development and commercialization of therapies that rely on the intravitreal injection of drugs into the eye. The goal is to deliver drugs more effectively and precisely to the site of action, thus increasing the effectiveness of the treatment. The company focuses on the treatment of diseases of the posterior segment of the eye, such as age-related macular degeneration, diabetic retinopathy, or retinal vein occlusions. The various divisions of Clearside Biomedical Inc include research and development, clinical trials, manufacturing and marketing of therapies, as well as marketing and sales. The company places great importance on collaboration with leading scientists and regulatory bodies to ensure the effectiveness and safety of their products. Clearside Biomedical Inc's products include various innovative therapies for intravitreal injection, such as the drug Zuprata. Zuprata is a steroid specifically developed for the treatment of diseases of the posterior segment of the eye and has high efficacy. The drug is injected directly into the vitreous humor of the eye and has the advantage of being longer-lasting than other steroids. Another product of Clearside Biomedical Inc is the CLS-TA implant. The implant is based on an innovative technology that allows for continuous delivery of drugs over a longer period of time. The implant is directly implanted into the posterior part of the eye and can help increase the efficacy of drugs and reduce the number of necessary injections. Clearside Biomedical Inc has made significant progress in recent years and has successfully conducted several clinical trials. In 2019, the company received approval from the US Food and Drug Administration (FDA) for the marketing of Zuprata for the treatment of macular edema associated with uveitis. Overall, Clearside Biomedical Inc has a promising future. The company relies on innovative technologies and close collaboration with leading experts in the field of ophthalmology to develop new therapies and provide patients with better treatment options. Clearside Biomedical is one of the most popular companies on Eulerpool.com.

Clearside Biomedical SWOT Analysis

Strengths

Clearside Biomedical Inc has several notable strengths that contribute to its success in the industry. Firstly, the company possesses advanced technology and expertise in developing novel drug therapeutics targeting eye diseases. This allows them to stay at the forefront of innovation and gain a competitive edge.

Secondly, Clearside Biomedical Inc has established strategic partnerships with pharmaceutical companies, enabling them to leverage resources, access wider markets, and increase their overall market presence. These partnerships also contribute to the company's financial stability and growth potential.

Additionally, Clearside Biomedical Inc has a strong research and development team that is dedicated to discovering breakthrough solutions for ophthalmology. Their commitment to scientific excellence and innovation enables them to continually develop and enhance their product portfolio.

Weaknesses

While Clearside Biomedical Inc has many strengths, they also face certain weaknesses that may impact their performance. One weakness is the dependency on strategic partnerships for market access and distribution. Any disruptions in these partnerships or potential conflicts of interest may pose a risk to the company's growth.

Another weakness is the need for substantial investments in research and development. The costs associated with drug discovery and clinical trials can be significant, and failure to secure adequate funding may hinder the company's ability to bring new products to market or pursue further advancements.

Opportunities

Clearside Biomedical Inc operates in an industry with numerous growth opportunities. The increasing prevalence of eye diseases, advancements in medical technology, and rising adoption of innovative treatment options present a favorable market environment for the company to expand its product offerings and penetrate new markets.

Moreover, Clearside Biomedical Inc can explore strategic collaborations and licensing agreements to further enhance their product portfolio and leverage existing market channels. By partnering with key industry players or acquiring complementary technologies, the company can strengthen its competitive position and diversify its revenue streams.

Threats

Like any business, Clearside Biomedical Inc also faces certain threats that may challenge its growth prospects. One significant threat is the regulatory environment governing the approval and reimbursement of pharmaceutical products. Compliance with stringent regulations, delays in approvals, or changes in reimbursement policies can impact the company's ability to commercialize its products effectively.

Additionally, the competitive landscape in the ophthalmology sector is intense, with numerous established players and emerging startups vying for market share. Clearside Biomedical Inc must continuously innovate and differentiate themselves to stay ahead of competitors and maintain their market position.

Clearside Biomedical Revenue by Segment

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Clearside Biomedical Revenue by Segment

Segmente20222021202020192018
License1.3 M USD----

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Clearside Biomedical Revenue by Segment

Segmente20222021202020192018
Other agreement-13,000 USD200,000 USD--
Other Agreements---105,000 USD-
Collaboration Agreements----30,000 USD
Other Agreement13,000 USD----
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Clearside Biomedical Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Clearside Biomedical historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Clearside Biomedical shares outstanding

The number of shares was Clearside Biomedical in 2023 — This indicates how many shares 61.807 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Clearside Biomedical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Clearside Biomedical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Clearside Biomedical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Clearside Biomedical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Clearside Biomedical.

Clearside Biomedical latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.13 -0.1  (21.14 %)2024 Q3
6/30/2024-0.14 -0.1  (27.38 %)2024 Q2
3/31/2024-0.14 -0.15  (-6.84 %)2024 Q1
12/31/2023-0.09 -0.08  (10.41 %)2023 Q4
9/30/2023-0.16 -0.15  (5.12 %)2023 Q3
6/30/2023-0.14 -0.15  (-3.81 %)2023 Q2
3/31/2023-0.14 -0.15  (-5.04 %)2023 Q1
12/31/2022-0.13 -0.16  (-24.51 %)2022 Q4
9/30/2022-0.03 -0.13  (-274.64 %)2022 Q3
6/30/2022-0.13 -0.13  (3.42 %)2022 Q2
1
2
3
4

Eulerpool ESG Scorecard© for the Clearside Biomedical stock

Eulerpool World ESG Rating (EESG©)

38/ 100

🌱 Environment

41

👫 Social

40

🏛️ Governance

33

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Clearside Biomedical shareholders

%
Name
Stocks
Change
Date
5.92700 % Whitmore (Bradford T)4,495,03404/15/2024
4.67437 % Hatteras Venture Partners3,545,04004/15/2024
3.74470 % The Vanguard Group, Inc.2,839,978349,1826/30/2024
3.41850 % Rosalind Advisors, Inc.2,592,59306/30/2024
3.09883 % Grace Brothers Management, LLC2,350,15204/15/2024
2.81646 % Armistice Capital LLC2,136,000-1,820,0006/30/2024
2.81216 % Carmignac Gestion2,132,74406/30/2024
1.03289 % BlackRock Institutional Trust Company, N.A.783,34734,0606/30/2024
0.88647 % Geode Capital Management, L.L.C.672,29730,0846/30/2024
0.76831 % Renaissance Technologies LLC582,68935,9006/30/2024
1
2
3
4
5
...
10

Clearside Biomedical Executives and Management Board

Dr. George Lasezkay

(71)
Clearside Biomedical President, Chief Executive Officer, Director (since 2017)
Compensation 1.53 M

Mr. Charles Deignan

(58)
Clearside Biomedical Chief Financial Officer
Compensation 876,029

Mr. William Humphries

(56)
Clearside Biomedical Independent Chairman of the Board
Compensation 124,312

Dr. Benjamin Yerxa

(57)
Clearside Biomedical Independent Director
Compensation 113,013

Mr. Richard Croarkin

(68)
Clearside Biomedical Independent Director
Compensation 96,562
1
2

Clearside Biomedical Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Bausch Health Stock
Bausch Health
SupplierCustomer0,640,770,640,580,700,62
REGENXBIO Stock
REGENXBIO
SupplierCustomer0,630,830,690,750,770,42
Aura Biosciences Stock
Aura Biosciences
SupplierCustomer0,610,300,830,04
Gerresheimer Stock
Gerresheimer
SupplierCustomer-0,28-0,510,110,570,760,08
1

Most common questions regarding Clearside Biomedical

What values and corporate philosophy does Clearside Biomedical represent?

Clearside Biomedical Inc represents a commitment to innovation, patient care, and scientific advancement. As a leading biopharmaceutical company, Clearside Biomedical is dedicated to developing and delivering transformative treatments for blinding diseases. With a focus on targeted therapies and specialized drug delivery, the company strives to improve patients' quality of life and offer hope where none existed before. Clearside Biomedical values a collaborative approach, working closely with healthcare professionals, researchers, and regulatory bodies to develop breakthrough solutions. By combining cutting-edge technology and extensive research, Clearside Biomedical aims to revolutionize the treatment landscape for ocular diseases.

In which countries and regions is Clearside Biomedical primarily present?

Clearside Biomedical Inc is primarily present in the United States.

What significant milestones has the company Clearside Biomedical achieved?

Clearside Biomedical Inc has achieved several significant milestones. One notable accomplishment is the successful completion of the HULK study, evaluating the efficacy and safety of CLS-TA for patients with macular edema associated with non-infectious uveitis. Additionally, the company received approval for their proprietary suprachoroidal CLS-TA drug-delivery platform by the U.S. Food and Drug Administration (FDA). Clearside Biomedical Inc also completed a public offering to raise funds for advancing their research and development efforts. Through their continuous innovations and regulatory achievements, Clearside Biomedical Inc demonstrates their commitment to improving treatment options for ophthalmic diseases.

What is the history and background of the company Clearside Biomedical?

Clearside Biomedical Inc is a reputable pharmaceutical company involved in the development of innovative ophthalmic treatments. Founded in 2011, Clearside Biomedical focuses on providing therapies for sight-threatening ocular diseases. The company primarily specializes in the use of proprietary SCS Microinjector® technology, which enables the precise delivery of drugs to the targeted site within the eye. With a strong commitment to advancing patient care, Clearside Biomedical conducts extensive research and clinical trials to develop effective solutions for diseases like macular edema and uveitis. With an impressive track record and a dedication to innovation, Clearside Biomedical Inc continues to make significant contributions to the field of ophthalmology.

Who are the main competitors of Clearside Biomedical in the market?

The main competitors of Clearside Biomedical Inc in the market are other biotechnology companies focusing on developing innovative ophthalmic therapies.

In which industries is Clearside Biomedical primarily active?

Clearside Biomedical Inc is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Clearside Biomedical?

Clearside Biomedical Inc's business model focuses on developing and commercializing innovative therapies to treat blinding diseases of the eye. The company utilizes its proprietary SCS Microinjector® to deliver targeted treatments to the affected areas of the eye, providing a non-surgical and convenient approach for patients. Clearside Biomedical Inc primarily focuses on developing treatments for conditions like macular edema, uveitis, and diabetic macular edema. By leveraging their expertise in ocular drug delivery, the company aims to improve patient outcomes and address unmet medical needs in the field of ophthalmology.

What is the P/E ratio of Clearside Biomedical 2024?

The Clearside Biomedical P/E ratio is -1.78.

What is the P/S ratio of Clearside Biomedical 2024?

The Clearside Biomedical P/S ratio is 45.8.

What is the Quality Investing of Clearside Biomedical?

The Quality Investing for Clearside Biomedical is 4/10.

What is the revenue of Clearside Biomedical 2024?

The expected Clearside Biomedical revenue is 1.43 M USD.

How high is the profit of Clearside Biomedical 2024?

The expected Clearside Biomedical profit is -36.87 M USD.

What is the business model of Clearside Biomedical

Clearside Biomedical Inc is a biopharmaceutical company that specializes in developing innovative therapies for the treatment of eye diseases. The company's business model is based on the development and marketing of safe and effective drugs that improve patients' vision and quality of life.

What is the Clearside Biomedical dividend?

Clearside Biomedical pays a dividend of 0 USD distributed over payouts per year.

How often does Clearside Biomedical pay dividends?

The dividend cannot currently be calculated for Clearside Biomedical or the company does not pay out a dividend.

What is the Clearside Biomedical ISIN?

The ISIN of Clearside Biomedical is US1850631045.

What is the Clearside Biomedical WKN?

The WKN of Clearside Biomedical is A2ALP6.

What is the Clearside Biomedical ticker?

The ticker of Clearside Biomedical is CLSD.

How much dividend does Clearside Biomedical pay?

Over the past 12 months, Clearside Biomedical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Clearside Biomedical is expected to pay a dividend of 0 USD.

What is the dividend yield of Clearside Biomedical?

The current dividend yield of Clearside Biomedical is .

When does Clearside Biomedical pay dividends?

Clearside Biomedical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Clearside Biomedical?

Clearside Biomedical paid dividends every year for the past 0 years.

What is the dividend of Clearside Biomedical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Clearside Biomedical located?

Clearside Biomedical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Clearside Biomedical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Clearside Biomedical from 12/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/6/2024.

When did Clearside Biomedical pay the last dividend?

The last dividend was paid out on 12/6/2024.

What was the dividend of Clearside Biomedical in the year 2023?

In the year 2023, Clearside Biomedical distributed 0 USD as dividends.

In which currency does Clearside Biomedical pay out the dividend?

The dividends of Clearside Biomedical are distributed in USD.

All fundamentals about Clearside Biomedical

Our stock analysis for Clearside Biomedical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Clearside Biomedical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.